# Kamuvudine-9 (K9) in Diabetic Macular Edema

> **NCT07458061** · PHASE1,PHASE2 · RECRUITING · sponsor: **Dr. Bryan Strelow** · enrollment: 10 (estimated)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** Placebo Tablet: BID
- **DRUG:** Kamuvudine K9

## Key facts

- **NCT ID:** NCT07458061
- **Lead sponsor:** Dr. Bryan Strelow
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2026-06
- **Final completion:** 2026-08
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07458061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07458061, "Kamuvudine-9 (K9) in Diabetic Macular Edema". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT07458061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*